department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Sagimet Biosciences Inc. ($SGMT) · pharmadog

PUBLIC COMPANY

$SGMTSagimet Biosciences Inc.

San Mateo, CA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

1Phase 11Phase 2

Metabolic Dysfunction-Associated Steatohepatitis (MASH or…

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Sagimet Biosciences Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$SGMT

SEC CIK

0001400118

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

Data sources

last refreshed 48m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$SGMT

Insider activity

source: SEC Form 4

open-market buys + sells

Feb 10, 26SELLHappel David· President & CEO12,101 sh @ $5.36−$65K↗
Feb 10, 26SELLMartins Eduardo Bruno· Chief Medical Officer3,640 sh @ $5.36−$20K↗
Feb 10, 26SELLRozek Elizabeth· Chief Legal & Admin. Officer2,622 sh @ $5.36−$14K↗
Feb 10, 26SELLChauche Thierry· Chief Financial Officer1,312 sh @ $5.36−$7K↗

routine RSU / option mechanics (6)

Feb 19, 26grantHappel David · President & CEO128,000 sh
Feb 19, 26grantHappel David · President & CEO256,000 sh
Feb 19, 26grantRozek Elizabeth · Chief Legal & Admin. Officer44,000 sh
Feb 19, 26grantChauche Thierry · Chief Financial Officer88,000 sh
Feb 19, 26grantChauche Thierry · Chief Financial Officer44,000 sh

Feb 19, 26

grant

Rozek Elizabeth · Chief Legal & Admin. Officer

88,000 sh

Active trials

phase1Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acnerecruitingn=128
phase1A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participantscompletedn=40
phase3A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASHwithdrawn
phase3A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosiswithdrawn
phase2Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)completedn=168
phase2Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)completedn=142
phase1A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Functioncompletedn=48